

REMARKS


The applicant has amended the claims of the subject continuation application to reflect the last status of the claims in the parent application Ser. No. 10/083,743. Claims 3 - 8 were previously amended. Claims 17 - 22 were previously presented. Claims 1, 2 and 9 - 12 are original. Claims 13 -16 were previously canceled. As a result of these amendments, claims 1 - 12 and 17 - 22 are now pending in the instant application. A clean copy of the claims currently pending in the application is given above.

No new matter has been introduced by virtue of the amendments made herein. Accordingly, applicants respectfully request their entry.

The applicant respectfully submits that the pending claims are fully allowable, and solicits the issuance of a notice to such effect. If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicant's undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: December 2, 2003



A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department
150 East 42nd Street - 5th Floor
New York, NY 10017-5755
(212) 733-3381